Molecular assessment of disease states in kidney transplant biopsy samples

Nature Reviews Nephrology

Volumn 12, Issue 9, 2016, Pages 534-548

  Halloran, Philip F ^a,b   Famulski, Konrad S ^a,b   Reeve, Jeff ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER;

ACUTE KIDNEY FAILURE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY MEDIATED REJECTION; BODY FLUID; CLASSIFIER; CLINICAL PROTOCOL; DIAGNOSTIC VALUE; GOLD STANDARD; HISTOLOGY; HISTORY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SURGICAL WOUND; SURVIVAL PREDICTION; URINARY TRACT DISEASE ASSESSMENT; GENETICS; GRAFT REJECTION; IMMUNOLOGY; KIDNEY; KIDNEY DISEASES; MOLECULAR DIAGNOSIS; PATHOLOGY; POSTOPERATIVE COMPLICATIONS;

GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSTIC TECHNIQUES; POSTOPERATIVE COMPLICATIONS;

EID: 84976299770     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2016.85     Document Type: Review

References (117)

1. Golub, T. R., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
2. Solin, L. J., et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J. Natl Cancer Inst. 105, 701-710 (2013).
3. Sparano, J. A., et al. Prospective validation of a 21 gene expression assay in breast cancer. N. Engl. J. Med. 373, 2005-2014 (2015).
4. Haas, M., et al. Banff 2013 meeting report: inclusion of C4d negative antibody-mediated rejection and antibody-associated arterial lesions. Am. J. Transplant. 14, 272-283 (2014).
5. Einecke, G., et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am. J. Transplant. 9, 2520-2531 (2009).
6. Loupy, A., et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J. Am. Soc. Nephrol. 52, 2267-2277 (2014).
7. Halloran, P. F., Merino Lopez, M., Salazar, I. D. R., & Chang, J. Clinical subclassifiation of ABMR phenotypes: recognizing variation in presentation [abstract]. Am. J. Transplant. 5 (Suppl. 3), 1458 (2015).
8. Mengel, M., et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am. J. Transplant. 12, 563-570 (2012).
9. Sis, B., et al. Isolated endarteritis and kidney transplant survival: a multicenter collaborative study. J. Am. Soc. Nephrol. 26, 1216-1227 (2015).
10. Salazar, I. D. R., Lopez, M. M., Chang, J., & Halloran, P. F. Reassessing the significance of v lesions in kidney transplant biopsies. J. Am. Soc. Nephrol. 26, 3190-3198 (2015).
11. Racusen, L. C., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 55, 713-723 (1999).
12. Halloran, P. F., Langone, A. J., Helderman, J. H., & Kaplan, B. Assessing long-term nephron loss: is it time to kick the CAN grading system?. Am. J. Transplant. 4, 1729-1730 (2004).
13. Solez, K., et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am. J. Transplant. 7, 518-526 (2007).
14. Martin-Gandul, C., Mueller, N. J., Pascual, M., & Manuel, O. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am. J. Transplant. 15, 3024-3040 (2015).
15. Furness, P. N., et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am. J. Surg. Pathol. 27, 805-810 (2003).
16. Furness, P. N., & Taub, N. International variation in the interpretation of renal transplant biopsies: report of the CERTPAP project. Kidney Int. 60, 1998-2012 (2001).
17. Reeve, J., et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am. J. Transplant. 13, 645-655 (2013).
18. Middleton, D., Jones, J., & Lowe, D. Nothing's perfect: the art of defining HLA-specific antibodies. Transplant. Immunol. 30, 115-121 (2014).
19. Visentin, J., et al. Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: prevalence, relevance, and impact on organ allocation. Transplantation 98, 738-744 (2014).
20. Gombos, P., et al. Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am. J. Transplant. 13, 2075-2082 (2013).
21. Gebel, H. M., & Bray, R. A. In search of perfection. Am. J. Transplant. 13, 1951-1952 (2013).
22. Lefaucheur, C., et al. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J. Am. Soc. Nephrol. 27, 293-304 (2015).
23. Loupy, A., et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N. Engl. J. Med. 369, 1215-1226 (2013).
24. Hidalgo, L. G., et al. De novo donor specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am. J. Transplant. 9, 2532-2541 (2009).
25. Lachmann, N., et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 87, 1505-1513 (2009).
26. Zou, Y., Stastny, P., Susal, C., Dohler, B., & Opelz, G. Antibodies against MICA antigens and kidney-transplant rejection. N. Engl. J. Med. 357, 1293-1300 (2007).
27. Halloran, P. F. Transplantation: autoantibodies-epiphenomena or biological clues. Nat. Rev. Nephrol. 9, 705-706 (2013).
28. Menon, M. C., Keung, K. L., Murphy, B., & O'Connell, P. J. The use of genomics and pathway analysis in our understanding and prediction of clinical renal transplant injury. Transplantation http://dx.doi. org/10.1097/TP.0000000000000943 (2015).
29. Lo, D. J., Kaplan, B., & Kirk, A. D. Biomarkers for kidney transplant rejection. Nat. Rev. Nephrol. 10, 215-225 (2014).
30. Flechner, S. M., et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am. J. Transplant. 4, 1475-1489 (2004).
31. Kurian, S. M., et al. Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling. Am. J. Transplant. 14, 1164-1172 (2014).
32. Roedder, S., et al. A three-gene assay for monitoring immune quiescence in kidney transplantation. J. Am. Soc. Nephrol. 26, 2042-2053 (2015).
33. Li, L., et al. A peripheral blood diagnostic test for acute rejection in renal transplantation. Am. J. Transplant. 12, 2710-2718 (2012).
34. Roedder, S., et al. The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med. 11, e1001759 (2014).
35. Suthanthiran, M., et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N. Engl. J. Med. 369, 20-31 (2013).
36. Anglicheau, D., et al. Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis. Transplantation 93, 1136-1146 (2012).
37. Sarwal, M., et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N. Engl. J. Med. 349, 125-138 (2003).
38. Naesens, M., et al. Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. Kidney Int. 80, 1364-1376 (2011).
39. Park, W. D., Griffin, M. D., Cornell, L. D., Cosio, F. G., & Stegall, M. D. Fibrosis with inflammation at one year predicts transplant functional decline. J. Am. Soc. Nephrol. 21, 1987-1997 (2010).
40. Vitalone, M. J., et al. Transcriptome changes of chronic tubulointerstitial damage in early kidney transplantation. Transplantation 89, 537-547 (2010).
41. Dosanjh, A., et al. Genomic meta-analysis of growth factor and integrin pathways in chronic kidney transplant injury. BMC Genomics 14, 275 (2013).
42. Einecke, G., et al. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J. Clin. Invest. 120, 1862-1872 (2010).
43. Mengel, M., et al. The molecular phenotype of six-week protocol biopsies from human renal allografts: reflections of prior injury but not future course. Am. J. Transplant. 11, 708-718 (2011).
44. Reeve, J., Halloran, P. F., & Kaplan, B. Common errors in the implementation and interpretation of microarray studies. Transplantation 99, 470-475 (2015).
45. Sellares, J., et al. Predictors of response to treatment in biopsy-diagnosed T cell-mediated rejection [abstract]. Am. J. Transplant. 12 (Suppl. 3), 322 (2012).
46. Halloran, P. F., et al. Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J. Am. Soc. Nephrol. 26, 1711-1720 (2015).
47. Sellares, J., et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and non-adherence. Am. J. Transplant. 12, 388-399 (2012).
48. Limmathurotsakul, D., et al. Fool's gold: why imperfect reference tests are undermining the evaluation of novel diagnostics: a reevaluation of 5 diagnostic tests for leptospirosis. Clin. Infect. Dis. 55, 322-331 (2012).
49. Brealey, S. D., Scally, A. J., Hahn, S., & Godfrey, C. Evidence of reference standard related bias in studies of plain radiograph reading performance: a meta-regression. Br. J. Radiol. 80, 406-413 (2007).
50. Waikar, S. S., Betensky, R. A., Emerson, S. C., & Bonventre, J. V. Imperfect gold standards for kidney injury biomarker evaluation. J. Am. Soc. Nephrol. 23, 13-21 (2012).
51. Rutjes, A. W., Reitsma, J. B., Coomarasamy, A., Khan, K. S., & Bossuyt, P. M. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol. Assess. 11, 50 (2007).
52. Reitsma, J. B., Rutjes, A. W., Khan, K. S., Coomarasamy, A., & Bossuyt, P. M. A review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard. J. Clin. Epidemiol. 62, 797-806 (2009).
53. Sis, B., et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am. J. Transplant. 9, 2312-2323 (2009).
54. Famulski, K. S., et al. Molecular phenotypes of acute kidney injury in human kidney transplants. J. Am. Soc. Nephrol. 23, 948-958 (2012).
55. Halloran, P. F., et al. Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM). Am. J. Transplant. 13, 2865-2874 (2013).
56. Madill-Thomsen, K. S., Reeve, J., Bohmig, G., Eskandary, F., & Halloran, P. F. Molecular assessment of kidney transplant biopsies performs similarly in medulla and cortex [abstract 1006]. Am. J. Transplant. 16 (Suppl. 3), 16 (2016).
57. Hodgin, J. B., et al. A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am. J. Pathol. 177, 1674-1686 (2010).
58. Vitalone, M. J., et al. Transcriptional perturbations in graft rejection. Transplant 99, 1882-1893 (2015).
59. Scian, M. J., et al. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am. J. Transplant. 11, 2110-2122 (2011).
60. Szczesniak, M. W., & Makalowska, I. lncRNA-RNA interactions across the human transcriptome. PLoS ONE 11, e0150353 (2016).
61. Lorenzen, J. M., et al. Long noncoding RNAs in urine are detectable and may enable early detection of acute T cell-mediated rejection of renal allografts. Clin. Chem. 61, 1505-1514 (2015).
62. Mimura, I., Kanki, Y., Kodama, T., & Nangaku, M. Revolution of nephrology research by deep sequencing: ChIP-seq and RNA-seq. Kidney Int. 85, 31-38 (2014).
63. Broin, O., et al. A pathogenesis-based transcript signature in donor-specific antibody-positive kidney transplant patients with normal biopsies. Genom. Data 2, 357-360 (2014).
64. Gupta, A., et al. Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies. Kidney Int. 89, 217-225 (2016).
65. Mueller, T. F., et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am. J. Transplant. 7, 2712-2722 (2007).
66. Venner, J. M., et al. Molecular landscape of T cell-mediated rejection in human kidney transplants: prominence of CTLA4 and PD ligands. Am. J. Transplant. 14, 2565-2576 (2014).
67. Venner, J. M., Hidalgo, L. G., Famulski, K. S., Chang, J., & Halloran, P. F. The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am. J. Transplant. 15, 1336-1348 (2015).
68. Venner, J. M., Famulski, K. S., Reeve, J., Chang, J., & Halloran, P. F. Relationships among injury, fibrosis, and time in human kidney transplants. JCI Insight 1, e85323 (2016).
69. Mueller, C. G., et al. Polymerase chain reaction selects a novel disintegrin proteinase from CD40 activated germinal center dendritic cells. J. Exp. Med. 186, 655-663 (1997).
70. Mueller, C. G., et al. Mannose receptor ligand-positive cells express the metalloprotease decysin in the B cell follicle. J. Immunol. 167, 5052-5060 (2001).
71. Sharma, P., & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205-214 (2015).
72. Pauken, K. E., & Wherry, E. J. SnapShot: T cell exhaustion. Cell 163, 1038 (2015).
73. Wherry, E. J., & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486-499 (2015).
74. Lipson, E. J., et al. Tumor regression and allograft rejection after administration of anti-PD 1. N. Engl. J. Med. 378, 896-898 (2016).
75. Parkes, M. D., Halloran, P. F., & Hidalgo, L. G. Gene expression microarray analysis of purified CD16 stimulated human NK cells and indication biopsies supports a CD16 mediated role for NK cells in antibody-mediated kidney rejection [abstract 1997]. Am. J. Transplant. 16 (Suppl. 3), 16 (2016).
76. Min, X., et al. Expression and regulation of complement receptors by human natural killer cells. Immunobiology 219, 671-679 (2014).
77. Ross, G. D., & Vetvicka, V. CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin. Exp. Immunol. 92, 181-184 (1993).
78. Halloran, P. F., Merino, L. M., & Barreto, P. A. Identifying subphenotypes of antibody-mediated rejection in kidney transplants. Am. J. Transplant. 16, 908-920 (2016).
79. Cosio, F. G., Gloor, J. M., Sethi, S., & Stegall, M. D. Transplant glomerulopathy. Am. J. Transplant. 8, 492-496 (2008).
80. Aubert, O., et al. Phenotype and outcome of antibody-mediated rejection due to pre-existing and de novo DSA in kidney recipients [abstract 1336]. Am. J. Transplant. 16 (Suppl. 3), 16 (2016).
81. Platt, J. L. Accommodation: how you see it, how you don't. Am. J. Transplant. 11, 2007-2008 (2011).
82. Cohen, D., et al. Pros and cons for C4d as a biomarker. Kidney Int. 81, 628-639 (2012).
83. Reeve, J., et al. Diagnosing rejection in renal transplants: a comparison of molecular-and histopathology-based approaches. Am. J. Transplant. 9, 1802-1810 (2009).
84. Goes, N., et al. Disturbed MHC regulation in the interferon ? knockout mouse. J. Immunol. 155, 4559-4566 (1995).
85. Goes, N., Urmson, J., Ramassar, V., & Halloran, P. F. Ischemic acute tubular necrosis induces an extensive local cytokine response: evidence for induction of interferon ?, transforming growth factorβ 1, granulocyte-macrophage colony-stimulating factor, interleukin 2 and interleukin 10. Transplantation 59, 565-572 (1995).
86. Einecke, G., et al. Loss of solute carriers in T cell mediated rejection in mouse and human kidneys: an active epithelial injury - repair response. Am. J. Transplant. 10, 2241-2251 (2010).
87. Einecke, G., et al. The early course of renal allograft rejection: defining the time when rejection begins. Am. J. Transplant. 9, 483-493 (2009).
88. Famulski, K. S., et al. Kidney transplants with progressing chronic kidney diseases express high levels of acute kidney injury transcripts. Am. J. Transplant. 13, 634-644 (2013).
89. Famulski, K. S., et al. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am. J. Transplant. 7, 2483-2495 (2007).
90. Einecke, G., et al. Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. Am. J. Transplant. 8, 1434-1443 (2008).
91. Mengel, M., et al. Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts. Am. J. Transplant. 9, 169-178 (2009).
92. Fukuda, A., et al. Urine podocin:nephrin mRNA ratio (PNR) as a podocyte stress biomarker. Nephrol. Dial. Transplant. 27, 4079-4087 (2012).
93. Yang, Y., et al. The two kidney to one kidney transition and transplant glomerulopathy: a podocyte perspective. J. Am. Soc. Nephrol. 26, 1450-1465 (2015).
94. Wickman, L., et al. Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases. J. Am. Soc. Nephrol. 24, 2081-2095 (2015).
95. Naik, A. S., et al. Quantitative podocyte parameters predict human native kidney and allograft half-lives. JCI Insight 1, e86943 (2016).
96. Schnermann, J. Homer, W. The juxtaglomerular apparatus: from anatomical peculiarity to physiological relevance. J. Am. Soc. Nephrol. 14, 1681-1694 (2003).
97. Schnermann, J., & Levine, D. Z. Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu. Rev. Physiol. 65, 501-529 (2003).
98. Schnermann, J. The juxtaglomerular apparatus: from anatomical peculiarity to physiological relevance. J. Am. Soc. Nephrol. 14, 1681-1694 (2003).
99. Komlosi, P., Fintha, A., & Bell, P. D. Unraveling the relationship between macula densa cell volume and luminal solute concentration/osmolality. Kidney Int. 70, 865-871 (2006).
100. Sellares, J., et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am. J. Transplant. 13, 971-983 (2013).
101. Jordan, M. I., & Mitchell, T. M. Machine learning: trends, perspectives, and prospects. Science 349, 255-260 (2015).
102. Tarca, A. L., Carey, V. J., Chen, X. W., Romero, R., & Draghici, S. Machine learning and its applications to biology. PLoS Comput. Biol. 3, e116 (2007).
103. Flach P. A. Machine Learning: The Art and Science of Algorithms That Make Sense of Data Cambridge Univ. Press, 2012).
104. Halloran, P. F., et al. Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: the INTERCOM study. Am. J. Transplant. 13, 2352-2363 (2013).
105. Reeve, J., Chang, J., Salazar, I. D. R., Lopez, M. M., & Halloran, P. F. Using molecular phenotyping to guide improvements in the histologic diagnosis of T cell-mediated rejection. Am. J. Transplant. 16, 1183-1192 (2016).
106. Gill, J. S., & Tonelli, M. Penny wise, pound foolish?. Coverage limits on immunosuppression after kidney transplantation. N. Engl. J. Med. 366, 586-589 (2012).
107. Wiebe, C., et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am. J. Transplant. 15, 2921-2930 (2015).
108. Wiebe, C., et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am. J. Transplant. 12, 1157-1167 (2012).
109. Modena, B. D., et al. Gene expression in biopsies of acute rejection and interstitial fibrosis/tubular atrophy reveals highly shared mechanisms that correlate with worse long-term outcomes. Am. J. Transplant. http://dx.doi.org/10.1111/ajt.13728 (2016).
110. Halloran, K., et al. Microarray analysis of endobronchial lung transplant biopsies: detection of T cell mediated inflammation in a safer biopsy type. J. Heart Lung Transplant. 35, S155-S156 (2016).
111. Halloran, K., et al. Microarray analysis of transbronchial biopsies in lung transplant recipients detect expression signatures of T cell mediated inflammation. J. Heart Lung Transplant. 35, S234-S235 (2016).
112. Loupy, A., et al. The molecular landscape of antibody-mediated rejection in heart transplant patients: insights for mechanisms, activity and stage. Circulation (in press).
113. Halloran, B. P., et al. Molecular patterns in human ulcerative colitis and correlation with response to infliximab. Inflamm. Bowel Dis. 20, 2353-2363 (2014).
114. Boor, P., & Floege, J. Renal allograft fibrosis: biology and therapeutic targets. Am. J. Transplant. 15, 863-886 (2015).
115. Rockey, D. C., Bell, P. D., & Hill, J. A. Fibrosis - a common pathway to organ injury and failure. N. Engl. J. Med. 372, 1138-1149 (2015).
116. El Zoghby, Z. M., et al. Identifying specific causes of kidney allograft loss. Am. J. Transplant. 9, 527-535 (2009).
117. Bunnag, S., et al. FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post transplant but not with favorable outcomes. Am. J. Transplant. 8, 1423-1433 (2008).